Vulpes Life Sciences Fund buys more shares in Proteome Sciences plc

Proteome Sciences plc LON:PRM has received notification from Vulpes Life Sciences Fund that on 02 May 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,143,715 equivalent to 18.38% of Proteome Sciences’ total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,143,715 Ordinary Shares of the Company representing 18.38% of the issued share capital of the Company.

 
1.  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name                                                      Vulpes Life Sciences Fund 
2.  Reason for the Notification 
a)  Position/status                                           PCA of Martin Diggle (NED) 
b)  Initial notification/Amendment                            Initial notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                                      Proteome Sciences plc 
b)  LEI                                                       n/a 
4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
     each type of transaction; (iii) each date; and (iv) each place where transactions have been 
     conducted 
a)  Description of the Financial instrument, type of          Ordinary Shares of 1p each 
    instrument 
    Identification code                                       GB0003104196 
b)  Nature of the transaction                                 Purchase 
c)  Price(s) and volume(s)                                     100,000 Ordinary Shares at 5p per Ordinary Shares 
d)  Aggregated information: 
     -- Aggregated volume                                      100,000 Ordinary Shares of 1p each purchased at a price 
     -- Price                                                  of 5p per Ordinary Share 
e)  Date of the transaction                                   2 May 2017 
f)  Place of the transaction                                  London Stock Exchange, AIM Market (XLON)
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Proteome Sciences Plc

    More articles like this

    Proteome Sciences Plc

    Proteome Sciences plc Board Appointment

    Proteome Sciences plc (LON:PRM) has today announced that Mr Richard Dennis has today been appointed to the Board of Directors.  As communicated on 3 April 2017, when he joined the Company as its first Chief Commercial

    Proteome Sciences Plc

    Proteome Sciences plc License Agreement Extension

    Electrophoretics Ltd, a wholly owned subsidiary of Proteome Sciences plc (LON:PRM), is pleased to announce that it has signed an amendment to the exclusive License and Distribution Agreement with Pierce Biotechnology Inc., a part of Thermo Fisher

    Proteome Sciences Plc

    Proteome Sciences plc Notice of Results

    The Directors look forward to updating shareholders on the Company’s performance, and on the outlook for 2018, at the time they announce their 2017 full year results which are scheduled for release on 24 April 2018. 

    Proteome Sciences Plc

    Proteome Sciences plc accreditation for clinical stage contracts

    Proteome Sciences plc has this morning announced the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will now enable it to compete effectively for clinical stage contracts commanding routinely larger budgets; the benefits of this

    Proteome Sciences Plc

    Proteome Sciences sales and royalties have increased 40%

    Proteome Sciences LON:PRM has given DirectorsTalk its unaudited interim results for the six months ended 30 June 2017. Financial highlights: — Total revenues increased 21% to GBP1.36m (2016: GBP1.12m) — TMT(R) reagent sales and royalties increased